Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
MWN-AI** Summary
Aclarion, Inc., a healthcare technology company specializing in chronic low back pain solutions, has appointed Jason Brosniak as Commercial Director for the Eastern U.S. This move is aimed at enhancing the adoption and market presence of Aclarion’s innovative Nociscan technology, a diagnostic tool that utilizes biomarkers and AI algorithms to effectively identify painful versus non-painful lumbar discs. Brosniak brings over 20 years of MedTech experience, having successfully driven revenue growth in early-stage and high-growth companies through his previous roles at Relievant Medsystems, Kyphon, and Intrinsic Therapeutics.
Aclarion's CEO, Brent Ness, expressed that Brosniak’s appointment marks a significant step in bolstering the company’s commercial strategy, particularly in the densely populated Eastern U.S. market. With the increasing demand for Nociscan—highlighted by promising real-world evidence and ongoing national trials—Aclarion sees the need for dedicated resources to effectively engage physicians and streamline payer interactions.
In his new role, Brosniak aims to leverage his extensive commercial expertise to enhance the market penetration of Nociscan, thereby improving treatment precision for healthcare providers. He stated, “Aclarion has built a platform with the power to meaningfully improve decision-making for both physicians and patients.” His focus will include deepening relationships with payers and supporting providers in delivering data-driven care.
The recent appointment follows Aclarion’s recent growth initiatives, including the hiring of Dan Isherwood as UK Commercial Director, further indicating the company’s commitment to assisting the estimated 266 million individuals suffering from chronic low back pain worldwide. For further details about Nociscan or to find a center, visit Aclarion’s website.
MWN-AI** Analysis
Aclarion, Inc. has made a strategic move by appointing Jason Brosniak as Commercial Director for the Eastern U.S. This decision is likely to enhance Aclarion’s market penetration, particularly in engaging healthcare providers and expanding payer relationships for its innovative Nociscan technology. Brosniak's extensive background in MedTech, particularly in launching breakthrough technologies across spine and pain management sectors, positions him well to catalyze adoption in a region known for its dense population and high demand for chronic pain management solutions.
From a market perspective, this appointment arrives at a crucial juncture for Aclarion, with increased demand for Nociscan supported by real-world evidence trials. Given that Aclarion’s Nociscan uses advanced biomarkers and AI to assist clinicians in diagnosing chronic low back pain, the potential for widespread adoption is substantial. Jason Brosniak’s proven track record, which includes stints at major companies like Relievant Medsystems and Kyphon, signals to investors that the company is serious about capturing market share in a competitive landscape.
Investors should watch how quickly Aclarion can mobilize its resources under Brosniak's leadership to enhance payer engagement and scan volume. The ability to interface effectively with healthcare providers will be pivotal, particularly as Aclarion targets the estimated 266 million individuals suffering from chronic low back pain universally.
Furthermore, the focus on building robust commercial frameworks in the Eastern U.S. could imply potential revenue growth in coming quarters, making Aclarion's stock an intriguing prospect for long-term investment. As the company scales its presence, stakeholders should remain attentive to its strategic execution and market responsiveness, which will be critical to its financial performance in the evolving MedTech landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companies
- Strong track record of launching breakthrough technologies across spine, neurosurgery and pain management
- Strengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S.
BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the appointment of Jason Brosniak as Commercial Director, Eastern U.S.
Jason is a proven commercial leader with more than 20 years of experience accelerating revenue growth and building high-performing teams for high-growth MedTech companies, including roles at Relievant Medsystems (acquired by Boston Scientific), Kyphon (acquired by Medtronic), and Intrinsic Therapeutics. His background in successfully launching breakthrough technologies and establishing new market categories across spine, orthopedics, and pain management makes him exceptionally well-positioned to drive the adoption of Nociscan in the Eastern U.S.
“Jason’s hire represents another significant commercial milestone for the Company,” said Brent Ness, CEO of Aclarion. “The growing demand for Nociscan through real-world evidence trials, and the national CLARITY randomized controlled trial, necessitates additional commercial resources in the densely populated Eastern U.S. Jason brings the critical early-stage commercial experience in the spine and pain sector that we need to engage physicians and advance scan volume and payer engagement.”
“Aclarion has built a platform with the power to meaningfully improve decision-making for both physicians and patients,” said Jason Brosniak, Commercial Director, Eastern U.S., Aclarion. “With growing real-world evidence and increasing demand from clinicians, now is the right time to scale our commercial presence. I look forward to leveraging my early-stage, start-up experience to drive adoption of Nociscan, deepen payer engagement, and support providers who are committed to delivering more precise, data-driven care.”
Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine by objectively quantifying chemical biomarkers. This appointment follows the recent naming of Dan Isherwood as UK Commercial Director, underscoring the Company’s progress in expanding access for the estimated 266 million people globally who suffer from chronic low back pain.
To find a Nociscan center, view our site map here .
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes,” “will” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jessica Starman
media@elev8newmedia.com
FAQ**
How does the appointment of Jason Brosniak as Commercial Director impact Aclarion Inc.'s strategy for expanding the adoption of Nociscan in the Eastern U.S., particularly in relation to their Aclarion Inc. Warrant ACONW?
What specific metrics or KPIs will Aclarion Inc. use to measure the success of Nociscan's market penetration in the Eastern U.S. under Jason Brosniak's leadership, considering the context of the Aclarion Inc. Warrant ACONW?
In light of Aclarion Inc.'s focus on payer engagement, what strategies will be implemented to ensure that Nociscan is adopted by healthcare providers, particularly regarding the implications for the Aclarion Inc. Warrant ACONW?
Can you elaborate on how real-world evidence trials will contribute to the commercialization of Nociscan, and what role will it play in enhancing the value of Aclarion Inc. Warrant ACONW for investors?
**MWN-AI FAQ is based on asking OpenAI questions about Aclarion Inc. Warrant (NASDAQ: ACONW).
NASDAQ: ACONW
ACONW Trading
-12.21% G/L:
$0.0345 Last:
3,100 Volume:
$0.0393 Open:
